newsfilter
← Latest News
GlobeNewswire·

Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Transformative Period Led by Acquisition of TeraImmune Company to Prioritize Development of New TI-168 Treg Asset for Hemophilia A Continuing to Advance Neuromuscular Blockade (NMB) Portfolio at Modest Pace